Santen Pharmaceutical Co., Ltd.
SNPHF
Get informed when a big investor buys or sells
+ FollowMarket Cap$541.72B
Close$
Share Statistics
| Market cap | $541.72 Billion |
|---|---|
| Enterprise Value | $494.81 Billion |
| Dividend Yield | $0.25 (2.38%) |
| Earnings per Share | $115.04 |
| Beta | 0.24 |
| Outstanding Shares | 321,344,079 |
Return
| Return on Equity | 13.03% |
|---|---|
| Return on Assets | 9.41% |
| Return on Invested Capital | 13.93% |
Valuation & Multiples
| P/E Ratio | 14.14 |
|---|---|
| PEG | 65.76 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 1.69 |
| Enterprise Value to EBIT | 10.59 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.13
Average shareholder expectationRevenue Estimate
$432.79 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.18
Average shareholder expectationRevenue Estimate
$462.55 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Santen Pharmaceutical Co., Ltd.
3,968 employees
CEO: Takeshi Ito Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addr...